The US FDA has approved an updated label for Tremfya (guselkumab) for the treatment of active psoriatic arthritis.

The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and ...

The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes predictive of therapeutic response. But there is also ...

A new study has uncovered factors associated with sacroiliitis progression in patients with psoriatic arthritis, as well as ...

Psoriatic arthritis biologics square off, novel molecules and mechanisms, and old drugs ma ...

The FDA has approved a label expansion for the interleukin-23 inhibitor guselkumab to include the inhibition of structural ...

Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis. The data presented at the American College of Rheumatology Convergence ...

UCB (UCBJY) announced on Tuesday that its biologic medicine Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, an inflammatory condition ...

New study results suggest high-sensitivity C-reactive protein may provide a more accurate picture of disease activity in patients with psoriatic arthritis.

Metabolic comorbidities are mechanistically intertwined with psoriasis and PsA, with obesity reducing biologic responsiveness and insulin resistance potentially sustaining joint inflammation.